Menu
GeneBe

MYRF

myelin regulatory factor

Basic information

Region (hg38): 11:61752635-61788518

Previous symbols: [ "C11orf9" ]

Links

ENSG00000124920NCBI:745OMIM:608329HGNC:1181Uniprot:Q9Y2G1AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • encephalitis/encephalopathy, mild, with reversible myelin vacuolization (Limited), mode of inheritance: AD
  • cardiac-urogenital syndrome (Strong), mode of inheritance: AD
  • cardiac-urogenital syndrome (Strong), mode of inheritance: AD
  • encephalitis/encephalopathy, mild, with reversible myelin vacuolization (Limited), mode of inheritance: Unknown

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Encephalitis/encephalopathy, mild, with reversible myelin vacuolization; Cardiac-urogenital syndromeADCardiovascular; NeurologicEncephalitis/encephalopathy, which involves acute reversible encephalopathy in children, and is frequently associated with a trigger, such as a febrile illness, has been reported as being treatable with steroids; Cardiac-urogenital syndrome may involve congenital anomalies (eg, cardiac anomalies), which may benefit from early diagnosis and interventionCardiovascular; Gastrointestinal; Genitourinary; Neurologic; Pulmonary29265453; 29446546; 30070761; 30532227

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MYRF gene.

  • not provided (57 variants)
  • Inborn genetic diseases (35 variants)
  • Cardiac-urogenital syndrome (19 variants)
  • MYRF-related condition (9 variants)
  • Encephalitis/encephalopathy, mild, with reversible myelin vacuolization (5 variants)
  • not specified (4 variants)
  • MYRF-Related Disorders (2 variants)
  • Scimitar syndrome (2 variants)
  • Cardiac-urogenital syndrome;Encephalitis/encephalopathy, mild, with reversible myelin vacuolization (2 variants)
  • Heart, malformation of;Abnormality of the genitourinary system (1 variants)
  • Heart, malformation of;Abnormality of the genitourinary system;Congenital diaphragmatic hernia (1 variants)
  • Developmental disorder (1 variants)
  • Neurodevelopmental disorder (1 variants)
  • Dextrocardia (1 variants)
  • Encephalitis/encephalopathy, mild, with reversible myelin vacuolization;Cardiac-urogenital syndrome (1 variants)
  • Disorder of sexual differentiation (1 variants)
  • Non-immune hydrops fetalis (1 variants)
  • Heart, malformation of;Congenital diaphragmatic hernia;Abnormality of the genitourinary system (1 variants)
  • Seizure (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MYRF gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
4
clinvar
6
clinvar
12
missense
8
clinvar
57
clinvar
2
clinvar
2
clinvar
69
nonsense
8
clinvar
2
clinvar
10
start loss
0
frameshift
5
clinvar
6
clinvar
1
clinvar
12
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
1
clinvar
2
clinvar
4
splice region
1
1
non coding
1
clinvar
17
clinvar
18
Total 14 18 63 6 25

Variants in MYRF

This is a list of pathogenic ClinVar variants found in the MYRF region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-61755417-G-C MYRF-related disorder Likely benign (Dec 26, 2020)3035971
11-61755487-G-T Benign (May 13, 2021)1246473
11-61765707-C-T MYRF-related disorder Likely benign (Feb 01, 2021)3057910
11-61765838-CGTCCCTTCCCAGCCACTGACTCCTCCGAAATCTCCATAGTTCCCTGCAGGGAGGGGGCGGCTACTTCCCTGCTGGGGCTGGGGTCCTGGCTGGAGCTGAGCCGCCCCCCTTCCCCGCAGCTGCTTCCCTGACATCTCTGCTCCAGCCAGCTCGGCCTCCTACTCCCACGGGCAGCCTGCGATGCCTGGCTCCAGCGGGGTCCACCACCTGAGCCCCCCTGGGGGTGGACCCTCCCCGGGGCGCCATGGTCCCCTCCCACCCCCGGGCTACGGCACCCCGCTGAACTGCAACAACAACAACGGCATGGGCGCTGCCCCCAAGCCCTTCCCGGGGGGCACCGGGCCCCCCATCAAGGCTGAGCCCAAGGCTCCCTATGCCCCAGGGTGAGTAAGGGCAGGGAGTAGGGGGATACAGCGGCATAGGGGCAGGCAGGGAGCAGGGCTGTGGCCGTGACCTGGGAGGTGCTAGACACTGGCCTGGCATGGGATGGGCTGGGTGACTGGCTGTGCGTGGGCAGGTGAGGGAAGGGAGGATGAGTCCAGGTCAAGGGGGGACTCCTGGGCTTTGTTCTGAGGCAGTGGGCAGCCACAAAGCTTCTAAGCATGGGAGTGATGAGGGCTGACGTAAGTGCTAGAAAAATCTCGATGCTGTGTGGAGAGTGGACAGGAAGCGGCGGGACTGGAGGCTGTGACTGTTTACCTTCATGGGAACACCTGCATACCCGTGCACGCGCGCCAAGCCCACCCACTTACGCATCCAGCTGACGTGTACTGTGGCCACAGGAGCTGGCCCATGGCTCAGATGTGGCACCTCAGTTCCCCCCTACCCAAGCAAGCCTCATGGGGCCCAGAACCCAGGCCCTTCCCCCCATCTTTCTGAGGAGTCCACACCAAGGGCCTGACCCAGGGCTGAACCTTAGGCCTGGCTTTGACCAAAGGTTCCAGGCAGCCACCCGGCCAGCCAGACTCCAGGGCAGCTCCCGGGGCACATGCTCACAGCGGGAGGCTGGGAGCATGGGTCTGCAGGGGAGCTCAGGGCAAATGTAGGGGCCCCTGTCTCTGGGTGGAAGAGCATTAAAACACTAGGTGCATGAACTCTGTGTTCAGACAGCCTGGCTCCAACTTCAGCTTCCCCATTTATCAGCCGTCTGCCTCGGTAACCCATGGCCTCAGTTTCTTCTGTGAAGTGAGCCCTCAAATGCTTACCCCTCAAGATTATCGTGGGAAGCAACAAGGGCACAGAGGATGCCCTGGGTGCATGGTGGCCATGGACACATGGCCGGCCGTGCTTCCTGAGCTCCCTGGCTTTTGGGGAGAAGGGAGTGGAGGCCAGGCTTGGGGTGCCAGGGGTGAACCTTTGCTGCAGAAGGCAAACTGTTTGCTTGAGGCTGTGAGGCTGTTCCTAAACTACAGGCCCCTGGGGGCAGAGGGAGGAGAACTAACATTTGGTAAGCGCCTGCTGGTGCCCACTGCTGTATCATGTGCCTATGATTGCGTGAGCTCATCAGCCTTCCTGGGTATCCAGCTCCTGGGAGACCCCACAAGGAGCCCTGGCCACTGCTACCGTCAGGATTTTAATGGCACACTGAGGCTCAGAGAGGGAAAGGGGCTTGTCCAGAGCCACACAGGGACTCTGTGGGCAGGGCCACTCCAGGAAGGGACCCAGGGCCAGACCTGAGTCTAGGTGATAAACAAGACAGACATGAGGCTGGGTGTGGTGGCACACACCTGTAATCCCAGCACTTTGGAAGGCCAAGGTAGGCATATTGCTTGAGCCCAGGAGTTCAAGACCAGTCTGCAACATGATGAAACCCCATCTCTACAAAAAATACAAAAATTAGCTGGGTGTGGTGGCGTGTGCCTATAGTCCCAGCTACTCGAGAGGCTGAGGTGAGAGAATAGTTTGAGCCAGGGAGGTCGAGGCTACAGTGAGCTGTGATCATGCCACTGCTAGGGACAGAGTAAGACCCTGTCTCAAAAAAAAAAAAAAAAAAAAAAGGCCAGGTGCGGTGGCTCATGCCTGTAATCCCAGCACTTTGGCAGGCTGAAGTGGGCAGATCACTTGAGGCCTGGAGTTTGAGACCGGCCTGGGCAATATGGTGAAACCCTGTCTGTACTAAAAATACAAAAATTAGTTGGGTGTGGTGGCGCATGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCACAAGAATCGTTTGAACCTGGGAGGTGGAGGTTACAGTGAGTGGTGATTGTGCCACTGGACTCCAGCCTGGGTGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAAAAAGAAAGAAAAGAAAAAAAACAGACACACGGCTCTGCAGTGGCTCCTGAAGCCTAACTGGGGAGAGGTATTCACCAGTACATCTCCAAGTAGAGGAATAATCAGGTGCCAGAGGAACTTAAGAGGAGAGAACACAAGGTGCTGTGGACTTGGGGCATGGGACTGCAGGGACTGCAGGGTGTGAAAGACCTTAACACATTACAGAAGGCCTGGCCATTGTCAGGGAAGTACAGGACGGAGTGGCAGCCCAGGGGGCCTGAGGCTGTGGCGAGGAGTATGGGTTTGAGTCCCCATACACGTTTTTGTATCATTCACACAAAACCTGCAGGGTCTGTGTTCTTGAATCGTTGTATAGGTTTCTACATGAGGCCCCGAAGGTGGGTGGGTGGCTGGCACAGGGATGCAGGGGGACTCTGGAGCCAGCCCCAGGGCTGTGTCCACAACAGGGCCATGGCCTCTCTGGCAGTTCCCTGGGCATGGGAATGGGGAGTTGCTCCAGATGTGGGGACCAGGGATGGCCAAAGAGCTGGATCCCATATGGCCACAGCCTTCCACTTGCTGGGTGAGCACAGGGTTCACGCAGGACGTGTTGACCTCTTGGGTTGAGTTTGTTCTTTTTCCTGAACACTGATAAAAGTGAAACCTGCAAGAAAAAAATAAACCCAGGCCCGGTGGTGCTGGCTCCCTTCCCAGTCCACACCTGCCTCTGGTGGGGCAGCCCCCCATGACCTGCTGAATGCCCTGAGGCCCAGCCCCCTAGGGCCCTGTGTTTCCAGGAAGCTGTGGGGCTTCAGTGGGTGCAGGAAGAGAGAAGAAGTCCTGGCCTTCGGTCTGGGGCGGGAGTCTTTGAGTCCCTGTGCCATCATCAAGGACACTAGTAACTGCCCCCCAAGTGCCCTGTAGGTCTGAGGGGATCCTGGGCGGTCCCCTACCCACAATTCGGCCCCAGGCCCTGCCAGGCACCCCAATGTGGGTGGTGCGGAGAAATGCCCCTAAGGGTGGATGTGACGAAACCTCAGTGTCGCCAGCTTCTGGGGGGCTGTGGGACCCTACCACGCAGAGAAGCTGCCCAGCTGGAAGGCAGAAGCTCAGCTGCTCACCCCCCGGCCCCTTCCCCTGGCTCTCGCAGCACACTGCCGGACTCTCCCCCAGACTCGGGCTCCGAGGCCTACTCCCCCCAGCAGGTGAATGGTGAGTCCAGCGGGCACCGCCCTCCTGCTCCAGGGTTTGGGCAAGTAGTTGGGGCGGCCTTATCAGGGAGGTAGGGGAGGAGGGAGGGGGCCAGCGGCTGCCCAACGGGCTGAGATTATCGCTGGTCAAATACTCCCTGGCGCTTGGCTATTGTTTCCCCACGGGCGGGTGGGGAGCCTGGCCCTGCCTCTGAGCAAGTATCCCCGCGGTGATGCCACCCGCCTGCCCGCCTGCGCCATCATGGACGCACCCTTCGGCGGTAAGTGGGTGGCTGGGGAAGGCCGTGGGTGCAGCCTGGGTGCAGGCTTCCCAGGCCGGGCCCACCTCACCTTAGAGGGTGCTCAGGGGTGCCCTGGCCCCCAGGTGGCCAAGAGCAGAACCACCGCGGGAGCAGGCTCCCCGCAGTCCGGATTGGGGTCAAGAGTTCTGTTTATCTTACCAAAAACATCCCTGGAATGCCTCCTGGGGAACAAAGGGAGCTGGGGCCTCCCCGCTCAGGCTGGGGGGCTGGCCCCTGAGAGCCCAGAAGAGGGACTGCCTGCCGGAGAGGGGAACACTGGGCAGGCCTGGGCTGGGGGTCTCCGGAGACGCCTTCCTGAGGCCCAGAGGAGGAGCAGGCCTCAGAGGAGATGGGGACGGAGGGGGACCTTTAGATTTGGGTTGGATTCTCCTGGTCCAGCCTGGGGGCAGGAGGTGGCTAGGATGAGGTGAAAGGCTGCCCCTCCTTGGGCAGGTTTGTGCCTCCCTGCCCAGGCCTCTAGTAGGTGGCTGACCAACGGCCCTCCCACCTAGGGTAGGTGGGGGGCAGCCCCCGGGCTTGGCTCAGGACGGGGTGGAAGCAGGAGACTCTGCCTTGGGGAGGACAGTGCCCAGGAGCCTGAGTGAGGTTGGTCTCAGATGCCCGCTCCCCCATCTCTCCTGCAGAGCCCCACCTCCTGCGCACGATAACCCCTGAGACACTGTGCCACGTGGGAGTGCCCTCCCGCCTGGAGCATCCGCCCCCACCTCCAGCCCACTTGCCAGGCCCCCCGCCACCCCCACCACCCCCACCTCACTACCCTGTCCTGCAGCGGGATCTGTACATGAAGGCCGAGCCCCCGATCCCCCACTACGCTGCCATGGGGCAGGGGCTGGTGCCCACTGATCTTCACCACACCCAGCAGTCCCAGATGCTGCACCAGCTCCTGCAGCAGCACGGAGCTGAGTAAGACGTGGGTGGCTGGCTCCATGGGGTGGGAAGGTGGGGTACAGGGACCAGGGTGGGCAGGGCGGCGGGCAGGCCAGAGAGGGAGGTAGGGACCGGGATGCACCCAGGGAGGGCAGAAGGCTCTGCAGGGCAGATGGGGGTAACATATTTATACATGTTTACCCAGCAATACCTTGAGGGGTTTACAGCCATGGCTAATTGCTCACAACTACCTTATCTGGTGGGCACAGGTAGGTAAACTGAGGCTCTGATGGGGGAAATGTCCCGTCCAGATCATGAGCCAGGGGCAGAGCCAGGACTGGGCCCGGGGCTGTGCTCTTACCCAGACCCCAGTGATTTTGCAGCTGTCTCATGGAACCCTCAGGTTTCTGAGGAGTCTTCTTCCTAGACCCAAGCCCCCGACTCTGACTCAACCTGCACGATTGTCTTTTCATCTGTTTTACATGTGGAGATTCCATGAAAGGTTTAGTTCAAAGGAAGGTTCTGCTGTCAAAACATTTTGTAAACCAGAAGGGGAAGGAGTGCCGTGCGGAAGCTCCCCTTCCCTGGTTTTTGTGGCCCAGGCCCTCTGTGGCTTGTTTCTGATCACAGGGCCTGCTCTCCATAGAGCCCCCACTATAAAGGGTGACCTTGAGTGTGACACTGCAGGCAGGGACAAACTCATTCATTCCTCAAGCGATTGCTGTGATTCTGTAAGCCAGCCCTGTTGCTGGGCATGATGGAGACACCAAGTCAGGTGTGGCTCCTGTCCACAGTCTGGGGGAAGCGAAGAGTGACAGAAGCAGAAAATGACAGCACAGAGCAATGGGGAGTAGGAGGAGGCAAAGCCTGAGGGCTTCCTGAAGGAGGTGTCCTCTGGGCGGGGCACATCCTGGCCCAAACAGGCTAGAGAGGGGAGAGAGGTGGATACTACCCAGTGGGAGGGGCTCGGGGAGAGCCAGCCCCCACGGCGCACACTTCTGTTTCCCCAGGCTCCCTACACACCCCTCCAAGAAGAGGAAGCACTCTGAATCCCCCCCCAGCACCCTCAATGCCCAGATGCTGAATGGAATGATCAAACAGGAGCCTGGGACCGTGACAGCCCTGCCTCTGCACCCCACTCGAGCCCCATCGCCACCCTGGCCTCCCCAGGGTCCGCTCTCCCCGGGCCCTGGTTCCTTGCCTCTCAGCATTGCCCGTGTCCAGACACCGCCTTGGCACCCGCCAGGTGCCCCCTCCCCAGGTACATGGCTGGCCAACTCTTCAAGGTGGGGTGTGGGACCCAAGGTGCAGGGCCCACATGGGCGTTCCCTCCCTCCAGGCCTCCTGCAGGACAGTGACAGCCTCAGTGGCTCCTACCTGGACCCCAACTACCAGTCCATCAAGTGGCAG-C Cardiac-urogenital syndrome Pathogenic (Jun 08, 2023)3235908
11-61765973-C-T MYRF-related disorder Likely benign (Mar 01, 2019)3045108
11-61765977-G-A MYRF-related disorder Benign (Sep 10, 2019)3043481
11-61765994-C-T MYRF-related disorder Likely benign (Oct 25, 2022)3047759
11-61766050-G-A Inborn genetic diseases Uncertain significance (Sep 27, 2022)2366952
11-61766057-T-TG Heart, malformation of;Abnormality of the genitourinary system;Congenital diaphragmatic hernia Likely pathogenic (-)996740
11-61766074-C-T Inborn genetic diseases Uncertain significance (Jul 20, 2021)2368207
11-61766100-C-T Uncertain significance (Mar 11, 2021)2434003
11-61766101-C-T Inborn genetic diseases Uncertain significance (Jan 03, 2024)3169607
11-61766112-A-C Inborn genetic diseases Likely benign (Jan 04, 2022)2269114
11-61766122-A-T Inborn genetic diseases Uncertain significance (Mar 22, 2023)2527955
11-61766129-C-G Developmental disorder Uncertain significance (Mar 04, 2021)1343185
11-61766136-A-G Disorder of sexual differentiation Likely pathogenic (Aug 17, 2021)1202589
11-61766146-G-A Inborn genetic diseases Uncertain significance (Oct 05, 2022)2317208
11-61766167-CG-C Pathogenic (Feb 01, 2021)1176284
11-61766173-GCACCGGGCCCCCCATC-T Cardiac-urogenital syndrome Pathogenic (Apr 06, 2019)635276
11-61766208-C-T Cardiac-urogenital syndrome;Encephalitis/encephalopathy, mild, with reversible myelin vacuolization Uncertain significance (Aug 13, 2021)1696610
11-61766325-A-T Benign (May 13, 2021)1268050
11-61766436-T-C Benign (May 13, 2021)1245970
11-61769111-G-A Benign (May 13, 2021)1230875
11-61769256-G-A MYRF-related disorder Likely benign (Oct 18, 2021)3047490
11-61769263-A-G MYRF-related disorder Likely benign (Oct 04, 2022)3032250

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MYRFprotein_codingprotein_codingENST00000278836 2735877
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.008.37e-8125724051257290.0000199
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense3.294567010.6500.00004287418
Missense in Polyphen168300.680.558743146
Synonymous1.162702950.9140.00001962345
Loss of Function6.55253.90.03710.00000264595

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002970.0000297
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.000.00
European (Non-Finnish)0.00007930.0000264
Middle Eastern0.00005440.0000544
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Myelin regulatory factor: Constitutes a precursor of the transcription factor. Mediates the autocatalytic cleavage that releases the Myelin regulatory factor, N-terminal component that specifically activates transcription of central nervous system (CNS) myelin genes (PubMed:23966832). {ECO:0000269|PubMed:23966832}.; FUNCTION: Myelin regulatory factor, N-terminal: Transcription factor that specifically activates expression of myelin genes such as MBP, MOG, MAG, DUSP15 and PLP1 during oligodendrocyte (OL) maturation, thereby playing a central role in oligodendrocyte maturation and CNS myelination. Specifically recognizes and binds DNA sequence 5'-CTGGYAC-3' in the regulatory regions of myelin- specific genes and directly activates their expression. Not only required during oligodendrocyte differentiation but is also required on an ongoing basis for the maintenance of expression of myelin genes and for the maintenance of a mature, viable oligodendrocyte phenotype (PubMed:23966832). {ECO:0000269|PubMed:23966832}.;

Recessive Scores

pRec
0.106

Intolerance Scores

loftool
rvis_EVS
-1.08
rvis_percentile_EVS
7.24

Haploinsufficiency Scores

pHI
0.224
hipred
Y
hipred_score
0.572
ghis
0.564

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
gene_indispensability_score

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Myrf
Phenotype
vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Gene ontology

Biological process
regulation of transcription by RNA polymerase II;proteolysis;oligodendrocyte development;central nervous system myelination;positive regulation of myelination;central nervous system myelin maintenance;positive regulation of transcription, DNA-templated;oligodendrocyte differentiation
Cellular component
nucleus;nucleoplasm;cytoplasm;endoplasmic reticulum membrane;Golgi apparatus;cytosol;integral component of membrane
Molecular function
DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;peptidase activity;sequence-specific DNA binding